Turns out the agencies have a bit of say in that and we will have to wait until they opine.
Once it becomes clear what the path forward is on AD only then will Missling begin negotiations on a partnership.
So I think your prognostications are premature and based on nothing.
There was never any prospect of a pharma partnership this year or any other year, nor any prospect that the so-called phase 2B/3 AD trial would be pivotal.